Objective To systematically review the literature and assess the diagnostic value of biomarkers in detection of late-onset left ventricular (LV) dysfunction in childhood cancer survivors (CCS) treated with anthracyclines. Methods We systematically searched the literature for studies that evaluated the use of biomarkers for detection of LV dysfunction in CCS treated with anthracyclines more than 1 year since childhood cancer diagnosis. LV dysfunction definitions were accepted as an ejection fraction</p
Aim: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxici...
Abstract Background Anthracycline-induced cardiac tox...
Background Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-t...
Contains fulltext : 202718.pdf (publisher's version ) (Closed access)OBJECTIVE: To...
Objective: To systematically review the literature and assess the diagnostic value of biomarkers in ...
Background Plasma biomarkers may aid in the detection of anthracycline-related cardiomyopathy (ACMP)...
Background Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-t...
Background: Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-...
PURPOSE: Echocardiographic surveillance for asymptomatic left ventricular systolic dysfunction (ALVS...
Abstract Aims Childhood cancer therapy is associated with a significant risk of therapy‐related card...
Background: Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-...
Background:The majority of childhood cancer survivors (CCSs) have been exposed to cardiotoxic treatm...
University of Minnesota M.S. thesis. Major: Clinical research. Advisor: Daniel A. Mulrooney, M.D., M...
Purpose of the Review As the number of cancer survivors increases due to early screening and modern ...
BACKGROUND: Plasma biomarkers may aid in the detection of anthracycline-related cardiomyopathy (ACMP...
Aim: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxici...
Abstract Background Anthracycline-induced cardiac tox...
Background Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-t...
Contains fulltext : 202718.pdf (publisher's version ) (Closed access)OBJECTIVE: To...
Objective: To systematically review the literature and assess the diagnostic value of biomarkers in ...
Background Plasma biomarkers may aid in the detection of anthracycline-related cardiomyopathy (ACMP)...
Background Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-t...
Background: Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-...
PURPOSE: Echocardiographic surveillance for asymptomatic left ventricular systolic dysfunction (ALVS...
Abstract Aims Childhood cancer therapy is associated with a significant risk of therapy‐related card...
Background: Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-...
Background:The majority of childhood cancer survivors (CCSs) have been exposed to cardiotoxic treatm...
University of Minnesota M.S. thesis. Major: Clinical research. Advisor: Daniel A. Mulrooney, M.D., M...
Purpose of the Review As the number of cancer survivors increases due to early screening and modern ...
BACKGROUND: Plasma biomarkers may aid in the detection of anthracycline-related cardiomyopathy (ACMP...
Aim: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxici...
Abstract Background Anthracycline-induced cardiac tox...
Background Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-t...